<DOC>
	<DOCNO>NCT00721149</DOCNO>
	<brief_summary>This trial evaluate safety effectiveness catheter ablation PAF . The investigational catheter study NAVISTAR® THERMOCOOL® irrigated-tip catheter . At time study , NAVISTAR® THERMOCOOL® Catheter FDA-approved commercial distribution U.S. treating patient Type I atrial flutter drug refractory monomorphic sustain ventricular tachycardia post myocardial infarction . The catheter approve use Europe endocardial ablation treat cardiac arrhythmia .</brief_summary>
	<brief_title>NAVISTAR® THERMOCOOL® Catheter Radiofrequency Ablation Symptomatic Paroxysmal Atrial Fibrillation- Treatment Use Study</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<criteria>Patients symptomatic PAF three ( 3 ) AF episodes six ( 6 ) month prior enrollment , one must document . Documentation may include electrocardiogram ( ECG ) , transtelephonic monitor ( TTM ) , Holter monitor ( HM ) , telemetry strip . Failure least one AAD PAF [ class I III AV nodal block agent beta blocker ( BB ) calcium channel blocker ( CCB ) ] evidence recurrent symptomatic PAF , intolerable side effect due AAD . Signed Patient Informed Consent Form . Age 18 year old . Able willing comply pre , post followup testing requirement . Atrial fibrillation secondary electrolyte imbalance , thyroid disease , reversible non cardiac cause . Previous ablation atrial fibrillation . Patients amiodarone therapy time previous six ( 6 ) month . AF episode last long 30 day terminate via cardioversion . Any valvular cardiac surgical procedure . CABG procedure within last 180 day ( six month ) . Awaiting cardiac transplantation cardiac surgery within next 360 day ( 12 month ) . Documented leave atrial thrombus imaging ( e.g . TEE ) . History document thromboembolic event within past one ( 1 ) year . Diagnosed atrial myxoma . Presence implant ICD . Significant pulmonary disease , ( e.g . restrictive pulmonary disease , constrictive chronic obstructive pulmonary disease ) disease malfunction lungs respiratory system produce chronic symptom . Significant congenital anomaly medical problem opinion investigator would preclude enrollment study . Women pregnant ( history menstrual period pregnancy test history consider unreliable ) . Acute illness active systemic infection sepsis . Unstable angina . Myocardial infarction within previous 60 day ( two month ) . LVEF &lt; 40 % . History blood clot bleed abnormality . Contraindication anticoagulation ( i.e . heparin warfarin ) . Contraindication CT/MRA procedure . Life expectancy le 360 day ( 12 month ) . Enrollment investigational study evaluate another device drug . Uncontrolled heart failure NYHA class III IV heart failure . Presence intramural thrombus , tumor abnormality precludes catheter introduction manipulation . Presence condition precludes vascular access .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Paroxysmal Atrial Fibrillation</keyword>
	<keyword>Ablation</keyword>
	<keyword>Non-randomized</keyword>
</DOC>